biotech · Advanced Solid Tumors · Seasonal Allergic Rhinitis · PRME
Prime Medicine
Prime Medicine is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker PRME. Primary therapeutic focus areas include Advanced Solid Tumors, Seasonal Allergic Rhinitis, Artificial Intelli
60 First St, Cambridge, Massachusetts 02141, US HQ
2019 Founded
185 Employees
Public company Type
PRME · NYSE Ticker
Company details
- Status
- Public
- HQ
- 60 First St, Cambridge, Massachusetts 02141, US
- Founded
- 2019
- Employees
- 185
- Programs
- 17
- Drugs
- 6
- Patents
- 127
PG-011 nasal spray 0.6%(twice daily)
Phase 3 · small molecule · Seasonal Allergic Rhinitis
PG-011 nasal spray 0.6%(twice daily) for Seasonal Allergic Rhinitis is a Phase 3 program (small_molecule) at Prime Medicine with 1 ClinicalTrials.gov record(s).
Internal code PG-011-SAR-301(phase III)
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Prime Medicine
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Seasonal Allergic Rhinitis
- Status
- active
- Trials
- 1